Authors: | Zattarin, E.; Presti, D.; Mariani, L.; Sposetti, C.; Leporati, R.; Menichetti, A.; Corti, C.; Benvenuti, C.; Fucà, G.; Lobefaro, R.; Ligorio, F.; Provenzano, L.; Vingiani, A.; Del Vecchio, M.; Griguolo, G.; Sirico, M.; Bernocchi, O.; Marra, A.; Zagami, P.; Agostinetto, E.; Jacobs, F.; Di Mauro, P.; Esposito, A.; Giorgi, C. A.; Lalli, L.; Boldrini, L.; Giacchetti, P. P. B.; Schianca, A. C.; Guarneri, V.; Pedersini, R.; Losurdo, A.; Zambelli, A.; Generali, D.; Criscitiello, C.; Curigliano, G.; Pruneri, G.; de Braud, F.; Dieci, M. V.; Vernieri, C. |
Title: | Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors |
Abstract: | Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors remains unclear. In 428 patients evaluated, HER2-low status was independently associated with significantly worse PFS and OS when compared with HER2-0 status. Based on our findings, HER2-low status could become a new prognostic biomarker in this clinical setting. © 2023, The Author(s). |
Keywords: | controlled study; human tissue; unclassified drug; overall survival; biological marker; progression free survival; epidermal growth factor receptor 2; cohort analysis; multicenter study; hormonal therapy; estrogen receptor; observational study; protein serine threonine kinase inhibitor; cancer prognosis; advanced breast cancer; human; female; article; cyclin dependent kinase 4 inhibitor; cyclin dependent kinase 6 inhibitor; human epidermal growth factor receptor 2 negative breast cancer |
Journal Title: | npj Breast Cancer |
Volume: | 9 |
ISSN: | 2374-4677 |
Publisher: | Nature Publishing Group |
Date Published: | 2023-01-01 |
Start Page: | 27 |
Language: | English |
DOI: | 10.1038/s41523-023-00534-1 |
PROVIDER: | scopus |
PMCID: | PMC10110597 |
PUBMED: | 37069173 |
DOI/URL: | |
Notes: | Article -- Export Date: 1 May 2023 -- Source: Scopus |